Navigation Links
Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
Date:9/15/2008

d or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed with the SEC on March 14, 2008, as well as other filings by the company with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
3. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
4. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
5. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
6. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
9. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
10. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
11. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... HILL, N.C. , Aug. 22, 2014  As ... the healthcare sector, many leaders in this area are ... The Medical Affairs Consortium at Best ... a forum for sharing insights about the key challenges ... creating and sharing solutions through three virtual roundtable discussions ...
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... and Chinese Intravenous Catheter Industry Report 2014" report ... Chinese Intravenous Catheter Industry Report 2014 is a professional ... global intravenous catheter industry with a focus on the ... of the industry including definitions, classifications, applications and industry ...
(Date:8/22/2014)... 2014  - MediaLINC ... Today Lincor announced general availability of MediaLINC ... a range of education, entertainment and clinical content direct ... http://photos.prnewswire.com/prnh/20140822/702945) , " Lincor has ... patient engagement to bedside smart devices, " comments ...
Breaking Medicine Technology:Best Practices' Medical Affairs Consortium Survey Has Achieved Strong Participation 2Global and Chinese Intravenous Catheter Industry Report 2014 2Lincor Unveils Next Generation TV-based Patient Engagement Solution 2
... Meeting in Salt ... Lake City, ... that they have identified specific genetic markers,for scoliosis. The data from this ... spinal curve progression in,patients with Adolescent Idiopathic Scoliosis., This groundbreaking research ...
... 11 /PRNewswire/-- Cerimon,Pharmaceuticals, Inc., announced today positive results ... topical 15 mg (1%) diclofenac sodium,patch. The multi-center ... Obtain Relief Topically) study evaluated the safety and ... pain due to acute,mild-to-moderate ankle sprains. The study ...
Cached Medicine Technology:Researchers at Axial Biotech Develop a DNA Test for Scoliosis 2Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain 2Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain 3
(Date:8/23/2014)... August 23, 2014 A team of New ... last longer when preceded by surgery and delivered by an ... the new study. Click here to read it now ... the cases of mesothelioma patients who underwent hemithoracic ... radiotherapy dose to the shape of a tumor. Patients ...
(Date:8/23/2014)... 2014 The MPWMD Board of Directors voted ... as a sole source of water for commercial and industrial ... architect, Ron Brown of Archworks, LLC in Carmel, California. ... first time a water district in the State of California ... source. AWGs at this time can now be used ...
(Date:8/23/2014)... 23, 2014 Youth substance abuse is ... no different in Houston, TX. Substance abuse can happen ... to drug and alcohol dependency in higher numbers than ... beat substance abuse, but don’t know where to find ... can be a challenge because most treatment options are ...
(Date:8/22/2014)... The IT manager of Top10BestSEOHosting.com is a web ... He has recently announced that GoDaddy ( http://www.top10bestseohosting.com/go/GoDaddy.com/ ) ... , GoDaddy is a popular supplier of cheap web ... solutions at affordable rates. It offers three Linux shared ... depend on the length of the contract. The longest ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 AWeber, ... services that currently helps more than 120,000 small ... caught the attention of Shane Michaels, prompting an investigative ... crucial element for any online marketing campaign, despite what ... in the marketing world,” reports Michaels. “AWeber is a ...
Breaking Medicine News(10 mins):Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:Historical Moment in the Monterey Peninsula, Brings Drought Relief Solution to California, with the Help of EcoloBlue and AWG Technology 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2
... a woman,s eggs to deteriorate in quality with age, and ... choose an egg -- out of a stash of roughly ... the ovary be influenced to pick a "good" quality egg ... questions are much on the mind of fertility researcher Teresa ...
... of Oregon chemist Shih-Yuan Liu have successfully synthesized ... and isostructural to the fundamentally important benzene molecule. ... research and materials science, the boron-nitrogen substituted analogues ... areas. , In the Journal of the ...
... the odds of this cluster of heart risk factors, experts ... of developing metabolic syndrome -- a group of factors linked ... five common gene variations, researchers say. , But one additional ... , People with metabolic syndrome run four times the ...
... to 75 generic drugs at no cost ... for ... copays and coinsurance on 75 generic drugs that are used to,treat common ... help our members become more actively involved in their,health care. The program ...
... According to a recent,survey from the Deloitte Center ... percent of Americans are financially prepared for their future,health ... of consumers are,completely satisfied with their health plans. As ... respond to consumers, demand for,increased access to online tools, ...
... Processing Technology offers insight to fresh food ... ... in fresh tomatoes has resulted in a nationwide concern for,consumers unfamiliar with ... packaged commercially,via heat processing are still safe to eat. Unfortunately heat changes ...
Cached Medicine News:Health News:New photo 'op' for ovaries may solve some mysteries of infertility 2Health News:Researchers confirm benzene-like electron delocalization of important molecule 2Health News:Metabolic Syndrome May Be in the Genes 2Health News:Independence Blue Cross Waives Copays for Generics Used to Treat Certain Chronic Conditions 2Health News:Independence Blue Cross Waives Copays for Generics Used to Treat Certain Chronic Conditions 3Health News:Independence Blue Cross Waives Copays for Generics Used to Treat Certain Chronic Conditions 4Health News:As Consumers Feel Financial Burden of Increasing Health Care Costs, Health Plans Have Opportunity to Address Unmet Consumer Needs and Become Trusted Advisors 2Health News:As Consumers Feel Financial Burden of Increasing Health Care Costs, Health Plans Have Opportunity to Address Unmet Consumer Needs and Become Trusted Advisors 3Health News:As Consumers Feel Financial Burden of Increasing Health Care Costs, Health Plans Have Opportunity to Address Unmet Consumer Needs and Become Trusted Advisors 4Health News:Ultra-High Pressure Processing Eliminates Salmonella in Fresh Tomatoes 2
For the quantitative determination of alanine aminotransferase in human serum....
... for the quantitative determination of ... or plasma. Single vial, dry ... must be purchased separately for ... reaction. Wavelength: 340 nm. Linearity: ...
Urea nitrogen (BUN) liquid reagent is used for the kinetic quantitative determination of Urea Nitrogen (BUN) in human serum used in routine examination and monitoring of therapy and relapses....
Intended for the quantitative determination of urea nitrogen in serum. Reaction: kinetic. Wavelength: 340 nm. Linearity: 150 mg/dL (53.4 mmol/L urea) at 37C....
Medicine Products: